Wellgner Fernandes Oliveira Amador
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Wellgner Fernandes Oliveira Amador has a total of 62 co-authors. Here are the top co-authors by number of shared publications:
- Asad Iqbal
Bacha Khan Medical College, Mardan, Pakistan
3 shared publications - Milena Ramos Tomé
Universidade Federal de Campina Grande Campina Grande Brazil
3 shared publications - Isabelle Castro Vitor
Department of Medicine Federal University of the State of Rio de Janeiro Rio de Janeiro Brazil
2 shared publications - Ivo Queiroz
University of Wisconsin-Madison , Madison , Wisconsin, USA , wisc.edu
2 shared publications Juan Alejandro Pinilla Alarcón
CES University, School of Medicine, Colombia
2 shared publications- Maaz Ahmad
Bacha Khan Medical College, Paquistão
2 shared publications
Latest Publications
- 26 June 2026
- Published by Springer Nature in Updates in Surgery
- Vol. 78 (6) , 2813-2814
Correction: Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis
- 26 June 2026
- Published by Springer Nature in Updates in Surgery
- Vol. 78 (6) , 2813-2814
Correction: Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis
- Open Access
- 21 May 2026
- Published by Wiley in Liver International
- Vol. 46 (6) , e70673
Primary Sclerosing Cholangitis Recurrence After Liver Transplantation: A Systematic Review and Updated Meta‐Analysis
Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485
- 21 May 2026
- Published by Wiley in Liver International
- Vol. 46 (6) , e70673
Open AccessPrimary Sclerosing Cholangitis Recurrence After Liver Transplantation: A Systematic Review and Updated Meta‐Analysis
Background and Aims: Primary sclerosing cholangitis (PSC) is an immune‐mediated cholestatic liver disease. Liver transplantation (LT) remains the only definitive treatment for patients with advanced disease. However, recurrence of PSC (rPSC) after LT is still a significant clinical challenge. The aim of this study was to assess the prevalence and incidence of rPSC following transplantation and to identify factors associated with its occurrence. Methods: We conducted a systematic review and meta‐analysis of observational cohorts by searching PubMed, Embase and Cochrane for studies. Statistical analyses were conducted using R, applying a random‐effects model with 95% confidence intervals. Results: Twenty‐nine studies were included, comprising 4682 patients who underwent LT for PSC (63.7% male). Most data originated from Europe (51.7%) and North America (29.2%), with additional cohorts from Asia (13.7%), South America (2.8%) and Oceania (2.6%). The worldwide pooled prevalence of rPSC was 18.66% (95% CI 15.33–22.52; I 2 = 84%) between 1980 and 2024. As for the worldwide pooled incidence, rPSC occurred at 26.04 per 1000 person‐years (95% CI 19.30–32.78; I 2 = 76.1%). The continent with the highest rPSC prevalence was Oceania with 30.65% (95% CI 23.17–39.29; I 2 = 13.8%) and South America had the highest incidence with 39.97 per 1000 person‐years (95% CI 25.42–54.51). Younger recipient age (mean difference [MD] = 5.16 years, 95% CI 4.13–6.19; I 2 = 51.3%), male sex (risk ratio [RR] = 0.92, 95% CI 0.87–0.98; I 2 = 0%), post‐LT cyclosporine use (RR = 0.56, 95% CI 0.42–0.76; I 2 = 0%), acute rejection (RR = 0.64, 95% CI 0.49–0.83) and de novo IBD (RR = 0.63, 95% CI 0.40–0.99; I 2 = 0%) were associated with an increased risk of recurrence. Conclusions: Prevalence and incidence of rPSC post‐LT varied according to continents. Younger recipient age, male sex, de novo IBD, cyclosporine use post‐LT and acute rejection episodes were associated with a higher risk of recurrence. Trial Registration: PROSPERO ID: CRD420250645485
- Open Access
- 28 April 2026
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 46 (Sp. 1) , 47-59
Omadacycline for community-acquired infections: A systematic review and single-arm meta-analysis
Introducción. Las infecciones adquiridas en la comunidad suponen una carga considerable para los sistemas de salud y son causadas por diversos agentes patógenos que pueden presentar distintos grados de gravedad. El aumento de la resistencia microbiana complica el tratamiento, lo que destaca la necesidad de nuevas terapias. La omadaciclina, un nuevo antibiótico, tiene una actividad de amplio espectro contra agentes patógenos tanto grampositivos como gramnegativos, en particular los implicados en infecciones adquiridas en la comunidad.Objetivo. Evaluar la eficacia y seguridad de la omadaciclina para el tratamiento de infecciones adquiridas en la comunidad.Materiales y métodos. Se buscaron estudios aleatorizados y no aleatorizados sobre omadaciclina para infecciones adquiridas en la comunidad, en PubMed, Embase y Cochrane, sin restricciones de tiempo. Los resultados primarios fueron el éxito clínico al final del tratamiento y la evaluación posterior al tratamiento. Los resultados secundarios incluyeron el riesgo de eventos adversos. El análisis estadístico se hizo con el software R. Resultados. Se analizaron datos de diez estudios que incluyeron 1666 pacientes y que abordaron infecciones como neumonía, infecciones de heridas, celulitis, abscesos importantes, úlceras de las extremidades inferiores, erisipela, cistitis e infecciones óseas o articulares. El análisis mostró una tasa de éxito clínico del 90 % (1138 de 1264 pacientes; IC95%: 88 - 91) al final del tratamiento y del 84 % (1288 de 1534 pacientes; IC95%: 82 - 86) postratamiento. Ocurrieron eventos adversos en el 45 % de los casos (747 de 1662; IC95%: 32 - 59), con un 18 % que experimentaron problemas gastrointestinales (181 de 1008; IC95%: 13 - 24). La tasa de mortalidad fue del 0 % (0,8%) (13 pacientes; IC95%: 0 - 1).Conclusión. La omadaciclina es una opción prometedora para el tratamiento de las infecciones adquiridas en la comunidad.
- 28 April 2026
- Published by Instituto Nacional de Salud (Colombia) in Biomédica
- Vol. 46 (Sp. 1) , 47-59
Open AccessOmadacycline for community-acquired infections: A systematic review and single-arm meta-analysis
Introducción. Las infecciones adquiridas en la comunidad suponen una carga considerable para los sistemas de salud y son causadas por diversos agentes patógenos que pueden presentar distintos grados de gravedad. El aumento de la resistencia microbiana complica el tratamiento, lo que destaca la necesidad de nuevas terapias. La omadaciclina, un nuevo antibiótico, tiene una actividad de amplio espectro contra agentes patógenos tanto grampositivos como gramnegativos, en particular los implicados en infecciones adquiridas en la comunidad.Objetivo. Evaluar la eficacia y seguridad de la omadaciclina para el tratamiento de infecciones adquiridas en la comunidad.Materiales y métodos. Se buscaron estudios aleatorizados y no aleatorizados sobre omadaciclina para infecciones adquiridas en la comunidad, en PubMed, Embase y Cochrane, sin restricciones de tiempo. Los resultados primarios fueron el éxito clínico al final del tratamiento y la evaluación posterior al tratamiento. Los resultados secundarios incluyeron el riesgo de eventos adversos. El análisis estadístico se hizo con el software R. Resultados. Se analizaron datos de diez estudios que incluyeron 1666 pacientes y que abordaron infecciones como neumonía, infecciones de heridas, celulitis, abscesos importantes, úlceras de las extremidades inferiores, erisipela, cistitis e infecciones óseas o articulares. El análisis mostró una tasa de éxito clínico del 90 % (1138 de 1264 pacientes; IC95%: 88 - 91) al final del tratamiento y del 84 % (1288 de 1534 pacientes; IC95%: 82 - 86) postratamiento. Ocurrieron eventos adversos en el 45 % de los casos (747 de 1662; IC95%: 32 - 59), con un 18 % que experimentaron problemas gastrointestinales (181 de 1008; IC95%: 13 - 24). La tasa de mortalidad fue del 0 % (0,8%) (13 pacientes; IC95%: 0 - 1).Conclusión. La omadaciclina es una opción prometedora para el tratamiento de las infecciones adquiridas en la comunidad.
- 25 March 2026
- Published by Springer Nature in Updates in Surgery
- p. 1-9
Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis
Primary closure with negative pressure wound therapy (NPWT) has been investigated in patients with sacrococcygeal pilonidal sinus to enhance healing and reduce recurrence. To address existing controversies, we conducted a systematic review and meta-analysis comparing primary closure with NPWT versus non-NPWT (control) for treatment of pilonidal disease. PubMed, Embase, and Cochrane Library databases were searched from inception to December 2024 to identify studies comparing NPWT versus control in primary closure surgeries in pilonidal sinus. Statistical analyses were performed using R Software with a random-effects model. Six studies with a total of 479 patients were included, of whom 164 (34.2%) underwent NPWT. NPWT had an association with lower pain score 24 h postoperative (MD − 0.65 points; 95% CI − 0.81 to − 0.50), shorter return time to activities (MD − 2.57 days; 95% CI − 3.74 to − 1.4). However, there was no difference between groups in the time of wound closure (MD − 18.94; 95% CI − 41.68 to 3.80), rate of wound dehiscence (RR 1.03; 95% CI 0.50 to 2.14), hospital length of stay (MD − 3.05; 95% CI − 15.77 to 9.67), infection rates (RR 0.38; 95% CI 0.05 to 2.84), recurrence rates (RR 0.54; 95% CI 0.07 to 4.48), and pain 6 h post-operative, which showed a borderline trend favoring NPWT but did not reach statistical significance (MD − 1.19; 95% CI − 2.38 to 0.01). NPWT appears to shorten time to resume normal activities and pain 24 h postoperatively. Despite these promising results, more randomized clinical trials are needed for greater analysis.
- 25 March 2026
- Published by Springer Nature in Updates in Surgery
- p. 1-9
Negative pressure wound therapy in primary closure surgeries for pilonidal disease: a meta-analysis
Primary closure with negative pressure wound therapy (NPWT) has been investigated in patients with sacrococcygeal pilonidal sinus to enhance healing and reduce recurrence. To address existing controversies, we conducted a systematic review and meta-analysis comparing primary closure with NPWT versus non-NPWT (control) for treatment of pilonidal disease. PubMed, Embase, and Cochrane Library databases were searched from inception to December 2024 to identify studies comparing NPWT versus control in primary closure surgeries in pilonidal sinus. Statistical analyses were performed using R Software with a random-effects model. Six studies with a total of 479 patients were included, of whom 164 (34.2%) underwent NPWT. NPWT had an association with lower pain score 24 h postoperative (MD − 0.65 points; 95% CI − 0.81 to − 0.50), shorter return time to activities (MD − 2.57 days; 95% CI − 3.74 to − 1.4). However, there was no difference between groups in the time of wound closure (MD − 18.94; 95% CI − 41.68 to 3.80), rate of wound dehiscence (RR 1.03; 95% CI 0.50 to 2.14), hospital length of stay (MD − 3.05; 95% CI − 15.77 to 9.67), infection rates (RR 0.38; 95% CI 0.05 to 2.84), recurrence rates (RR 0.54; 95% CI 0.07 to 4.48), and pain 6 h post-operative, which showed a borderline trend favoring NPWT but did not reach statistical significance (MD − 1.19; 95% CI − 2.38 to 0.01). NPWT appears to shorten time to resume normal activities and pain 24 h postoperatively. Despite these promising results, more randomized clinical trials are needed for greater analysis.
- Open Access
- 9 January 2026
- Vol. 62, e25056
EFFECTIVENESS AND SAFETY OF SELECTIVE IL-12/23 RECEPTOR ANTAGONISTS IN MODERATE TO SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS.
Selective IL-12/23p40 receptor antagonists (IL-12/23RA) show promise for treating moderate to severe ulcerative colitis (UC), but their efficacy and safety are not fully understood. Objective: This systematic review and meta-analysis assess the effectiveness and safety of IL-12/23RA in UC. A systematic search of PubMed, Embase, Cochrane, and ClinicalTrials.gov was performed in December 2024. Randomized controlled trials (RCTs) comparing IL-12/23RA to placebo in moderate to severe UC were included. Outcomes included clinical and endoscopic remission, response rates, and adverse events (AEs). Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were pooled using a random-effects model. Nine RCTs (3,808 patients in the induction phase; 1,734 in the maintenance phase) were analyzed. IL-12/23RA enhanced clinical remission (induction: RR 2.63; 95%CI 2.05-3.36; maintenance: RR 1.99; 95%CI 1.63-2.44; all P<0.01) and endoscopic remission (induction: RR 2.36; 95%CI 1.70-2.20; maintenance: RR 1.96; 95%CI 1.63-2.37; all P<0.01). IL-12/23RA reduced serious AE in the induction phase (RR 0.40; 95%CI 0.27-0.69; P<0.01), while there was no difference during maintenance (RR 0.75; 95%CI 0.31-1.84; P=0.53). No differences were observed in overall AEs or specific AEs like headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-12/23RA showed superior effectiveness and similar safety when compared to placebo in moderate to severe UC.
- 9 January 2026
- Vol. 62, e25056
Open AccessEFFECTIVENESS AND SAFETY OF SELECTIVE IL-12/23 RECEPTOR ANTAGONISTS IN MODERATE TO SEVERE ULCERATIVE COLITIS: A SYSTEMATIC REVIEW, META-ANALYSIS AND TRIAL SEQUENTIAL ANALYSIS.
Selective IL-12/23p40 receptor antagonists (IL-12/23RA) show promise for treating moderate to severe ulcerative colitis (UC), but their efficacy and safety are not fully understood. Objective: This systematic review and meta-analysis assess the effectiveness and safety of IL-12/23RA in UC. A systematic search of PubMed, Embase, Cochrane, and ClinicalTrials.gov was performed in December 2024. Randomized controlled trials (RCTs) comparing IL-12/23RA to placebo in moderate to severe UC were included. Outcomes included clinical and endoscopic remission, response rates, and adverse events (AEs). Risk ratios (RR) and mean differences (MD) with 95% confidence intervals (CI) were pooled using a random-effects model. Nine RCTs (3,808 patients in the induction phase; 1,734 in the maintenance phase) were analyzed. IL-12/23RA enhanced clinical remission (induction: RR 2.63; 95%CI 2.05-3.36; maintenance: RR 1.99; 95%CI 1.63-2.44; all P<0.01) and endoscopic remission (induction: RR 2.36; 95%CI 1.70-2.20; maintenance: RR 1.96; 95%CI 1.63-2.37; all P<0.01). IL-12/23RA reduced serious AE in the induction phase (RR 0.40; 95%CI 0.27-0.69; P<0.01), while there was no difference during maintenance (RR 0.75; 95%CI 0.31-1.84; P=0.53). No differences were observed in overall AEs or specific AEs like headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-12/23RA showed superior effectiveness and similar safety when compared to placebo in moderate to severe UC.
- Open Access
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Open AccessEffect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- 5 October 2025
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 54 (10) , 103046
Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis
- 5 October 2025
- Published by Elsevier in Journal of Gynecology Obstetrics and Human Reproduction
- Vol. 54 (10) , 103046
Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: A systematic review and meta-analysis
- Open Access
Effectiveness and Safety of Selective IL-23 Receptor Antagonists in Moderate to Severe Ulcerative Colitis: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
Selective interleukin-23 receptor antagonists (IL-23RA) show promise for treating moderate to severe ulcerative colitis (UC) but their efficacy and safety are not fully understood. We performed a systematic review and meta-analysis of randomized controlled trials comparing IL-23RA with placebo in moderate to severe UC. Outcomes included clinical and endoscopic remission, response rates, and adverse events. Nine trials including 3808 patients in the induction phase and 1734 in the maintenance phase were analyzed. IL-23RA improved clinical remission (induction risk ratio 2.63, 95 percent confidence interval 2.05-3.36; maintenance 1.99, 95 percent confidence interval 1.63-2.44) and endoscopic remission (induction 2.36, 95 percent confidence interval 1.70-2.20; maintenance 1.96, 95 percent confidence interval 1.63-2.37). IL-23RA reduced serious adverse events in the induction phase (0.40, 95 percent confidence interval 0.27-0.69) with no difference during maintenance (0.75, 95 percent confidence interval 0.31-1.84). No significant differences were observed in overall adverse events or specific events such as headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-23RA showed superior effectiveness and similar safety compared with placebo in moderate to severe UC.
Open AccessEffectiveness and Safety of Selective IL-23 Receptor Antagonists in Moderate to Severe Ulcerative Colitis: A Systematic Review, Meta-Analysis and Trial Sequential Analysis
Selective interleukin-23 receptor antagonists (IL-23RA) show promise for treating moderate to severe ulcerative colitis (UC) but their efficacy and safety are not fully understood. We performed a systematic review and meta-analysis of randomized controlled trials comparing IL-23RA with placebo in moderate to severe UC. Outcomes included clinical and endoscopic remission, response rates, and adverse events. Nine trials including 3808 patients in the induction phase and 1734 in the maintenance phase were analyzed. IL-23RA improved clinical remission (induction risk ratio 2.63, 95 percent confidence interval 2.05-3.36; maintenance 1.99, 95 percent confidence interval 1.63-2.44) and endoscopic remission (induction 2.36, 95 percent confidence interval 1.70-2.20; maintenance 1.96, 95 percent confidence interval 1.63-2.37). IL-23RA reduced serious adverse events in the induction phase (0.40, 95 percent confidence interval 0.27-0.69) with no difference during maintenance (0.75, 95 percent confidence interval 0.31-1.84). No significant differences were observed in overall adverse events or specific events such as headache or nasopharyngitis. Trial sequential analysis confirmed sufficient sample size for clinical endpoints. IL-23RA showed superior effectiveness and similar safety compared with placebo in moderate to severe UC.
- 18 August 2025
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (6) , e574-e576
Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
- 18 August 2025
- Published by Wolters Kluwer Health in American Journal of Therapeutics
- Vol. 33 (6) , e574-e576
Intravenous Iron Therapy in Patients With Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis